Citrate Pharmacokinetics and Regional Citrate Anticoagulation in CRRT

Citrate Pharmacokinetics in Healthy Individuals and Critically Ill Patients and the Application of Regional Citrate Anticoagulation in Continuous Renal Replacement Therapy(RCA-CRRT).

Status

UNKNOWN

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT00948558

Enrollment

Registered

2009-07-29

Start date

2009-03-31

Completion date

2011-09-30

Last updated

2009-08-06

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Acute Kidney Failure With or Without:, Hepatic Insufficiency, MODS, Sepsis

Keywords

citrate anticoagulation, pharmacokinetic, critically ill, acute kidney failure

Brief summary

1. To compare the differences of citrate pharmacokinetics in healthy individuals and critically ill patients as well as the influential factors. 2. To validate a pharmacokinetic model which has been established in a formal paper. 3. To create a safe and effective RCA-CRRT protocol.

Interventions

None listed

Study design

Observational model

CASE_CONTROL

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

18 Years to 80 Years

Healthy volunteers

Yes

Inclusion criteria

* healthy individuals, none-pregnant * diagnosed with acute renal failure according to RIFLE criteria * ARF with hepatic insufficiency * ARF with MODS or sepsis * within informed consent

Exclusion criteria

* used drugs with citrate within one week * infused with blood,plasma or platelet or undergone plasma exchange therapy within 48 hours * serious alkalosis with PH\>7.55 * serious lactic acidosis * not in resuscitation state

Countries

China

Contacts

Primary ContactFeng Ding, Professor

ding_feng@hotmail.com86-02152888135

Outcome results